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Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to
improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of
recurrence.
Patients and methods: Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive
either adjuvant bevacizumab (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection
of an 8% difference in 5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant
metastasis-free interval (DMFI). Tumour and blood were analysed for prognostic and predictive markers.
Results: Patients (n¼1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56 years
(range 18–88 years). With 6.4-year median follow-up, 515 (38%) patients had died [254 (38%) bevacizumab; 261 (39%)
observation]; 707 (53%) patients had disease recurrence [336 (50%) bevacizumab, 371 (55%) observation]. OS at 5 years was 64%
for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82–1.16, P¼ 0.78). At 5 years, 51% were disease free on
bevacizumab versus 45% on observation (HR 0.85; 95% CI 0.74–0.99, P¼ 0.03), 58% were distant metastasis free on bevacizumab
versus 54% on observation (HR 0.91; 95% CI 0.78–1.07, P¼ 0.25). Forty four percent of 682 melanomas assessed had a BRAFV600
mutation. In the observation arm, BRAF mutant patients had a trend towards poorer OS compared with BRAF wild-type patients
(P¼ 0.06). BRAF mutation positivity trended towards better OS with bevacizumab (P¼ 0.21).
Conclusions: Adjuvant bevacizumab after resection of high-risk melanoma improves DFI, but not OS. BRAF mutation status
may predict for poorer OS untreated and potential benefit from bevacizumab.
VC The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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Introduction
Angiogenesis is a host-dependent hallmark of cancer [1] and vas-
cular endothelial growth factor (VEGF) is a key driver of angio-
genesis [2]. VEGF is over-expressed in melanoma and high levels
have been reported to be associated with poorer outcome [3–6].
Bevacizumab (Avastin
VR
, F. Hoffman-La Roche AG, Basel,
Switzerland) is a recombinant humanised monoclonal antibody
to VEGF licensed for treatment of several common cancers, with
modest activity reported in advanced melanoma [7]. Since VEGF
is a relevant target in melanoma, we carried out a UK multi-
centre, open-label, randomised controlled phase III trial of adju-
vant bevacizumab versus standard surveillance in patients with
resected cutaneous melanoma at high risk of recurrence.
The interim analysis of the AVAST-M trial when 1343 patients
had been recruited and followed for more than 1 year showed a
significant improvement in disease-free interval (DFI) with adju-
vant bevacizumab [hazard ratio (HR) 0.83 (95% confidence
interval [CI] 0.70–0.98), P¼ 0.03] [8], which was well tolerated.
We report the analysis of the primary overall survival (OS) end
point, mandated when all surviving patients had been on study
for at least 5 years.
Methods
The study design, eligibility criteria, stratification variables and treatment
schedules have been described previously in detail [8]. Briefly, patients at
least 16-year old with histological confirmation of completely resected
AJCC 7th edition stage IIB, IIC or IIIA–C cutaneous melanoma were eli-
gible for the trial. Written informed consent was obtained for all patients.
Multicentre Research Ethics Committee and regulatory approvals were
obtained. Patients were followed up at least annually for 10 years after
randomisation.
Eligible patients were randomly assigned to adjuvant bevacizumab
(7.5 mg/kg i.v. infusion once every 3 weeks for 1 calendar year) or surveil-
lance in a 1 : 1 ratio, stratified by primary tumour Breslow thickness, N
stage, primary tumour ulceration status and patient sex. Randomisation
occurred within 12 weeks of surgical resection and was carried out cen-
trally using a computer minimisation algorithm held at the Warwick
Clinical Trials Unit. This was an open-label trial.
Biomarker analyses
At trial entry, plasma lactate dehydrogenase (LDH) was measured by
local hospital laboratories for all patients. A patient was classed as having
raised LDH if the value was above the upper level of normal (ULN) for
their hospital. LDH was also measured centrally in plasma at baseline
(pre-randomisation), 3 and 12 months from trial entry. VEGF and sol-
uble VEGF receptor-1 (VEGFR1) were measured centrally by ELISA in
both plasma and serum samples at baseline and then at 3, 12 and
24 months in exploratory patient cohorts. BRAF and NRAS mutation sta-
tus were determined in archival tumour tissue using accredited methods.
Statistical analysis
Patients (n ¼ 1320; 660 patients per arm) were required to detect an 8%
increase in the 5-year OS rate (primary end point) from 40% to 48% with
85% power and a 5% significance level, equating to an HR of 0.80. OS
was defined as the time from date of randomisation until date of death
from any cause, or censored at the last known date alive. Analysis was
follow-up driven and pre-planned when all patients had been on study
for 5 years.
Secondary end points were DFI, distant metastasis-free interval
(DMFI), safety, toxicity and health-related quality of life (QoL). Adverse
events were only collected during treatment and were reported previously
[8]. Tertiary end points were to evaluate biological predictive and prog-
nostic markers. DFI was defined as the time from date of randomisation
until date of first tumour recurrence (including distant and locoregional
recurrence), or date of death due to melanoma. DMFI was defined as the
time from date of randomisation until date of first distant recurrent dis-
ease, or date of death due to melanoma. Survival from recurrence was
defined as the time between the date of first tumour progression (in any
site) and the date of death. Kaplan–Meier survival curves were con-
structed and a Cox proportional hazard model was used to obtain HRs
and associated 95% CIs. Multivariable Cox regression models were used
to adjust the treatment effect for stratification variables, to evaluate inde-
pendent prognostic factors of OS and DFI and to assess treatment inter-
actions. EORTC-QLQ-C30 QoL data were analysed by standardised area
under the curve (AUC) and compared across trial arms using Wilcoxon
rank sum tests. Mixed-effect models were used to assess whether VEGF
and VEGFR1 levels changed over time or differed across trial arms. LDH
levels measured over time were fitted as time-dependent continuous
covariates in a Cox regression model.
Two-sided P values and 95% CIs are reported. All analyses were carried
out on an intention-to-treat basis using the SAS statistical package.
Results
Between 18 July 2007 and 29 March 2012, 1343 patients were
randomised to either the bevacizumab (N¼ 671) or observation
(N¼ 672) arms. Seven hundred fifty-three (56%) patients were
male, their median age was 56 years (range 18–88 years), 364
(27%) patients had stage II melanoma, 195 (14%) had stage IIIA
and 784 (59%) had stage IIIB/C disease. Sentinel lymph node bi-
opsy (SLNB) was not mandated and 32% of patients in each arm
underwent SLNB. Other baseline characteristics were similar be-
tween groups and were reported in full previously [8]. Six hun-
dred eight two (51%) patients’ tumours were assessed for BRAF
and NRAS mutation status; BRAF V600 and NRAS mutations
were detected in 303 (44%) and 134 (20%) tumours tested.
With a median follow-up of 6.4 years, 515 (38%) patients had
died: 254 (38%) of patients in the bevacizumab arm, 261 (39%)
in the observation arm, 92% from metastatic melanoma on both
arms. Seven hundred seven (53%) patients had melanoma recur-
rence: 336 (50%) in the bevacizumab arm, 371 (55%) in the ob-
servation arm. Of the 707 patients who had a recurrence, 117
(16%) patients had locoregional recurrence only, 359 (51%) had
distant recurrence only and 231 (33%) had both locoregional and
distant recurrence. One hundred twelve (16%) received an im-
mune checkpoint inhibitor or targeted therapy as treatment for
recurrence, totalling 55 (16%) on the bevacizumab arm and 57
(15%) on the observation arm (Table 1).
Original article Annals of Oncology
1844 | Corrie et al. Volume 29 | Issue 8 | 2018
There was no significant difference in OS between trial arms
(HR for bevacizumab¼ 0.98; CI 0.82–1.16; P¼ 0.78, Figure 1A).
The 5-year OS rate was 64% for both arms (CI 61%–68% for bev-
acizumab, 60%–67% for observation). Multivariate analysis
identified disease stage, ECOG performance status, primary mel-
anoma Breslow thickness and sex as independently prognostic of
OS; trial arm remained non-significant (P¼ 0.92; Table 2). There
was no statistically significant interaction between any of these
variables and trial arm (Figure 2).
The 5-year DMFI rate was 58% (CI 54%–62%) for the bevaci-
zumab arm and 54% (CI 50%–58%) for the observation arm, but
this was not statistically significantly different (HR¼ 0.91; CI
0.78–1.07; P¼ 0.25, Figure 1B). The median DMFI for the bevaci-
zumab arm was not reached (CI 7.3 years to limit not reached)
and 9.6 years (CI 5.5–9.6 years) for the observation arm.
The significant improvement in DFI for those on the bevacizu-
mab arm reported at the interim analysis was maintained over
time (HR¼ 0.85; CI 0.74–0.99; P¼ 0.03, Figure 1C) and persisted
after adjustment for the stratification variables (HR¼ 0.86; CI
0.74–0.99; P¼ 0.04). Patients receiving bevacizumab had a higher
5-year DFI rate (51%; CI 47%–55%) compared with the observa-
tion arm (45%; CI 42%–49%). The median DFI for patients in
the bevacizumab arm was 63 months (CI, 44 months to limit not
reached) and 37 months (CI 30–50 months) for those in the ob-
servation arm.
A high percentage (89%) of QoL forms were completed. There
was no difference in overall QoL over the 5 years for the two trial
arms: median standardised AUC for the QLQ-C30 global health
scale was 81.7% [interquartile range (IQR) 69.8%–90.7%] for
patients on the bevacizumab arm and 81.9% (IQR 68.6%–
91.7%) on the observation arm (P¼ 0.52).
In the observation arm, BRAF mutant melanoma patients had
poorer OS compared with BRAF wild-type melanomas (P¼ 0.06,
Figure 3A). Overall, this effect was similar after adjustment for
disease stage, ECOG performance status, primary melanoma
Breslow thickness and sex (P¼ 0.08, Table 2). A trend for
improved OS with bevacizumab was only evident for the patients
with BRAF mutant melanomas (HR¼ 0.80; CI 0.57–1.13;
P¼ 0.21, Figure 3C) and not seen in the patients with BRAF wild-
type melanomas (HR¼ 1.17; CI 0.82–1.61; P¼ 0.34, Figure 3E).
BRAF mutant patients received more checkpoint inhibitors/tar-
geted therapy at recurrence (22% versus 9%, supplementary
Table S1, available at Annals of Oncology online), but the benefit
from bevacizumab was evident for DFI as well as OS (Figure 3D).
At trial entry 179 (13%) patients had plasma LDH levels above
the hospital reported ULN. Baseline LDH was not found to be
prognostic of DFI (HR¼ 1.01, CI 0.81–1.25, P¼ 0.97), DMFI
(HR¼ 1.10, CI 0.88–1.39, P¼ 0.40) or OS (HR¼ 1.05; CI 0.81–
1.35; P¼ 0.73). LDH measurements across three time-points—
baseline, 3 months and 12 months—were also assessed. After
Table 1. Details of melanoma recurrence and associated treatment of recurrence
Bevacizumab Observation Total
(N 5 671) (N 5 672) (N 5 1343)
N (%) N (%) N (%)
Patients with any recurrence 336 (50%) 371 (55%) 707 (53%)
Locoregional only 54 (16%) 63 (17%) 117 (16%)
Distant only 169 (50%) 190 (51%) 359 (51%)
Both locoregional and distant recurrence 113 (34%) 118 (32%) 231 (33%)
Treatment for any recurrence
Immune checkpoint inhibitors/targeted therapya 55 (16%) 57 (15%) 112 (16%)
Vemurafenib 27 34 61
Ipilimumab 19 17 36
Dabrafenib þ/ trametinib 16 8 24
Ipilimumab þ nivolumab 2 1 5
Pembrolizumab 2 2 4
Pazopanib 0 1 1
Vandetanib 1 0 1
Blinded ipilimumab, nivolumab or ipilimumabþnivolumab 0 2 2
Other systemic therapy 79 (24%) 97 (26%) 176 (25%)
Given as part of a clinical trial 9 19 28
Dacarbazine 56 59 115
Other cytotoxic chemotherapy 11 12 23
Other immunotherapy 3 5 8
Other biological agent 0 2 2
Surgery only 89 (26%) 119 (32%) 208 (29%)
Other (including radiotherapy) 66 (20%) 62 (17%) 128 (18%)
None 47 (14%) 36 (10%) 83 (12%)
aPatients could receive more than one line of treatment for recurrence; 98% patients receiving systemic therapy had distant metastatic disease.
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Figure 1. Overall survival (A), distant metastasis-free interval (B) and disease-free interval (C), by trial arm.
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fitting LDH as a time-dependent continuous covariate, LDH was
still not found to be prognostic of DFI (HR¼ 1.00, CI 0.96–1.03
per 50 unit increase, P¼ 0.81), DMFI (HR¼ 1.01, CI 0.97–1.05
per 50 unit increase, P¼ 0.56) or OS (HR¼ 1.02, CI 0.98–1.06
per 50 unit increase, P¼ 0.36).
Patients (N¼ 414; 198 in the bevacizumab arm, 216 in the ob-
servation arm) had VEGF and VEGFR1 plasma and serum
measurements at baseline and serially over the 2 years from ran-
domisation (supplementary Figure S1, available at Annals of
Oncology online). Neither baseline plasma nor serum VEGF were
prognostic factors for OS (HR¼ 1.02, CI 0.95–1.10 per 50 unit
increase, P¼ 0.53 for plasma; HR¼ 1.03, CI 0.98–1.07 per 50
unit increase, P¼ 0.21 for serum). Serum, but not plasma, VEGF
levels significantly fell over time in the bevacizumab-treated
Gender
Events/Patients
Treatment
Treatment events *Hazard Ratio & CI
(Treatment : Obs)
*HR & CI
(Treatment : Obs)Obs (O-E) Var
Disease stage
Interaction between 2 groups χ21= 0.3; P=.59
Heterogeneity between 3 groups χ22= 1.7; P=.42
Heterogeneity between 3 groups χ22= 3.4; P=.18
Heterogeneity between 4 groups χ23= 2.7; P=.44
Interaction between 2 groups χ21= 2.6; P=.10
Interaction between 2 groups χ21= 2.9; P=.09
Ulceration
II
III(N1a & N2a)
III(Other N)
Unknown
Breslow Thickness
Unknown
Performance status
Baseline LDH
ECOG=0
<=ULN
>ULN
ECOG=1
Male
Present
Absent
<=2mm
2-4mm
>4mm
Female
Stratified
159/377 157/376 1.01 (0.81, 1.26)
0.92 (0.70, 1.21)
0.98 (0.82, 1.16)
1.21 (0.84, 1.73)
0.85 (0.54, 1.33)
0.95 (0.77, 1.19)
0.99 (0.83, 1.18)
1.12 (0.86, 1.46)
0.81 (0.62, 1.05)
1.13 (0.72, 1.77)
0.97 (0.82, 1.16)
0.94 (0.68, 1.32)
0.80 (0.58, 1.11)
1.14 (0.86, 1.52)
1.03 (0.52, 2.07)
0.93 (0.77, 1.13)
1.40 (0.89, 2.19)
0.99 (0.83, 1.18)
0.95 (0.78, 1.14)
1.47 (0.92, 2.36)
1.01 (0.85, 1.20)
0.98 (0.82, 1.16)
0.97 (0.82, 1.16)
(P=.92)
(P=.76)
(P=.77)
(P=.91)
(P=.94)
(P=.78)
(P=.78)
1.0 79.0
49.7
128.7
–4.2
–3.1
5.7 29.7
19.2
79.7
128.6
54.0
55.7
19.0
128.7
35.0
37.2
48.5
8.0
128.7
109.0
128.0
108.7
17.3
126.0
128.7
0.0 0.5
Treatment better Obs better
1.0 1.5 2.0
19.1
–3.1
–3.7
–1.1
6.1
–11.9
–3.5
–2.0
–8.1
6.6
0.3
–3.3
–7.6
6.4
–1.3
–5.9
–3.1
6.7
0.8
2.3
104/296
261/672
(41.8%)
(35.1%)
(38.8%)
254/671
66/187 53/177
(42.2%)
(32.3%)
(37.9%)
(35.3%) (29.9%)
(29.6%)
(46.7%)
(38.8%)
40/135
168/360
37/141
151/343
254/671
114/262 102/256
124/32399/310
41/99 35/93
261/672254/671
67/198 73/201
81/202
91/217
16/52
261/672
68/203
103/221
254/671
213/602 223/593
38/79
261/672
40/67
253/669
16/49
(43.5%) (39.8%)
(38.4%)
(37.6%)
(38.8%)
(31.9%)
(41.4%)
(37.9%)
(33.8%) (36.3%)
(40.1%)
(41.9%)
(30.8%)
(38.8%)
(33.5%)
(46.6%)
(32.7%)
(37.9%)
(35.4%) (37.6%)
(48.1%)
(38.8%)
(59.7%)
(37.8%)
214/568 221/563
253/654
32/9138/88
252/656
254/671 261/672
(37.7%) (39.3%)
(35.2%)
(38.7%)
(43.2%)
(38.4%)
(37.9%) (38.8%)
261/672
(26.2%)
(44.0%)
(37.9%)
95/294
Stratified
Stratified
Stratified
Stratified
Stratified
Unstratified
* 95% CI 95% CI
Figure 2. Hazard ratio plot of the treatment effect by prognostic factors for overall survival.
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patients compared with observation (P< 0.0001 and P¼ 0.58, re-
spectively). Neither baseline plasma nor serum VEGFR1 were
prognostic factors for OS (HR¼ 0.85, CI 0.58–1.25 per 50 unit
increase, P¼ 0.41 for plasma; HR¼ 0.86, CI 0.60–1.22 per 50
unit increase, P¼ 0.40 for serum). Plasma VEGFR1 levels
increased during bevacizumab treatment compared with obser-
vation (P< 0.001). However, VEGFR1 serum results did not vary
over time (P¼ 0.75) or by trial arm (P¼ 0.92).
Discussion
AVAST-M represents the largest trial in a melanoma patient
population evaluating angiogenesis inhibition. This survival
analysis was pre-planned when all patients had been on
study for 5 years. With longer follow-up, the trial has confirmed
the interim finding that adjuvant bevacizumab improved
DFI [8]. The HR of 0.85 favouring bevacizumab is comparable
to the event-free survival HR of 0.86 reported for adjuvant
interferon in a recent meta-analysis [9]. However, while for ad-
juvant interferon this HR translated into a small OS benefit, this
was not the case for bevacizumab. The conditional power for
futility of the primary outcome of OS was less than 10%.
Therefore adjuvant bevacizumab cannot be recommended as a
standard adjuvant therapy after resection of melanoma at high
risk of recurrence.
The 64% 5-year OS rate for both observation and treatment
arms of the AVAST-M trial was notably higher than predicted
when the trial was designed. The original statistical premise was
based on the results of the UK AIM High trial, which recruited
patients with similar demographics between 1995 and 2000
[10]. Since then, improvements in healthcare and more accurate
staging have contributed to an upward trend in melanoma pa-
tient survival [11]. The step change is evident in observation
arms of other adjuvant melanoma trials: EORTC 18991
recruited stage III patients only between 2000 and 2003 and had
a 7-year OS of 46% [12], while the 5-year OS rate in the EORTC
18071 trial which recruited similar patients between 2008 and
2011 was 54% [13]. The AVAST-M observation arm carried out
even better, although one quarter of patients had lower risk
stage II disease.
During the time that AVAST-M was recruiting, MAP kinase
inhibitors and immune checkpoint inhibitors were approved for
treatment of metastatic melanoma and are now standard of care.
Only 16% of patients taking part in AVAST-M received these
drugs at recurrence and the proportions were equal between the
two trial arms, so we can be confident that treatment at recur-
rence cannot explain the lack of survival benefit from
Table 2. Multivariate analysis for overall survival for all trial patients and for the subgroup of patients for whom BRAF mutation status was assessed
All trial patients BRAF mutation status assessed
All trial
patients
Deaths Hazard ratio
(95% CI)
BRAF mutant BRAF WT Deaths Hazard ratio
(95% CI)
N (%) N (%) N (%) N (%) N (%)
Total 1343 303 379
Sex P ¼ 0.003 P ¼ 0.19
Male 753 (56%) 316 (42%) 1.31 (1.10-1.57) 156 (51%) 230 (61%) 167 (43%) 1.18 (0.92-1.51)
Females 590 (44%) 199 (34%) 1.00 147 (49%) 149 (39%) 113 (38%) 1.00
Breslow thickness of primary melanoma P ¼ 0.0003 P ¼ 0.004
<2.0 mm 399 (30%) 140 (35%) 1.00 126 (42%) 87 (23%) 83 (39%) 1.00
>2–4 mm 405 (30%) 149 (37%) 1.12 (0.89-1.42) 94 (31%) 108 (29%) 81 (40%) 1.16 (0.85-1.59)
>4 mm 438 (33%) 194 (44%) 1.53 (1.19-1.96) 65 (21%) 153 (40%) 101 (46%) 1.63 (1.16-2.27)
Unknown 101 (7%) 32 (32%) 0.75 (0.51-1.10) 18 (6%) 31 (8%) 15 (31%) 0.67 (0.38-1.17)
AJCC disease stagea P < 0.0001 P < 0.0001
II 364 (27%) 119 (33%) 1.00 52 (17%) 117 (31%) 55 (33%) 1.00
IIIA 195 (15%) 41 (21%) 0.78 (0.53-1.48) 56 (19%) 29 (7%) 23 (27%) 1.00 (0.59-1.70)
IIIB 495 (37%) 210 (42%) 1.89 (1.47-2.44) 130 (43%) 147 (39%) 127 (46%) 2.18 (1.53-3.12)
IIIC 289 (21%) 145 (50%) 2.27 (1.74-2.96) 65 (21%) 86 (23%) 75 (50%) 2.40 (1.65-3.51)
ECOG performance status P < 0.0001 P ¼ 0.001
0 1195 (89%) 436 (36%) 1.00 269 (89%) 345 (91%) 240 (39%) 1.00
1 146 (11%) 78 (53%) 1.64 (1.29-2.10) 34 (11%) 33 (9%) 39 (58%) 1.75 (1.24-2.46)
Trial arm P ¼ 0.92 P ¼ 0.83
Bevacizumab 671 (50%) 254 (38%) 1.01 (0.85-1.20) 132 (44%) 184 (49%) 128 (41%) 1.03 (0.81-1.30)
Observation 672 (50%) 261 (39%) 1.00 171 (56%) 195 (51%) 152 (42%) 1.00
BRAF status P ¼ 0.08
BRAF mutant 303 (100%) 0 129 (43%) 1.24 (0.97-1.59)
BRAF WT 0 379 (100%) 151 (40%) 1.00
aAJCC 7th edition.
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bevacizumab reported here. Central gene mutation testing for
just over half of recruited patients identified BRAF and NRAS
mutation rates of 44% and 20%, respectively. These proportions
reflect those in metastatic melanoma populations, suggesting sta-
bility over time.
We used this large-scale adjuvant trial to explore potential
prognostic and predictive biomarkers. Although LDH may be of
prognostic value in metastatic disease, this was not the case after
melanoma resection. Our study represents the most comprehen-
sive analysis of angiogenesis biomarkers associated with a
melanoma patient cohort conducted to date, but has not identi-
fied any immediate clinical value in measuring VEGF or VEGFR1
after melanoma surgery. Other circulating factors associated with
angiogenesis [14] could be considered in future melanoma trials
evaluating angiogenesis inhibitors.
The most common melanoma genetic mutation, BRAF, is a
near-perfect biomarker predictive of sensitivity to BRAF tar-
geted therapies in both advanced and high-risk resected melan-
oma [15]. Its role as a prognostic marker in each of these disease
stages is, however, controversial [16]. Survival differences
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according to BRAF mutation status reported for patient cohorts
after resection of primary melanomas have been inconsistent
[17–19]. In our study, we saw a trend in poorer OS for BRAF
mutant patients compared with BRAF wild-type patients, al-
though this did not reach statistical significance. We also identi-
fied a trend towards enhanced OS from adjuvant bevacizumab
limited only to the subgroup of patients with BRAF mutated
tumours. BRAF mutation status was recently reported to de-
scribe populations with differing OS after immune checkpoint
inhibitors [20]. BRAF V600E is pro-angiogenic in several
human tumour models [21, 22], while VEGF has wider regula-
tory function beyond angiogenesis, including on immune cells
[23–25]. Exploratory studies combining bevacizumab with ipili-
mumab [26] or atezolizumab [27, 28] have reported early effi-
cacy signals. Our findings raise the hypothesis that combining
bevacizumab with adjuvant immune checkpoint inhibitors may
benefit high-risk BRAF mutant melanoma patients, who in our
study had a poorer prognosis than patients with tumours lack-
ing the mutation.
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